Akasa you must be very proud when someone still remember you. 🙈 🙈
ETLee8 ( Date: 22-Nov-2021 22:09) Posted:
|
Obviously he is one the many " Yang Warriors" .
 
 
jackjack ( Date: 22-Nov-2021 20:10) Posted:
|
And AKASA still says pandemic they cannot make money when only make money? Wait pandemic over they might even perform worse than this. He claims medtecs is doing ppe which is hard to get approval and they are leader in this this industry, whereby they make less than 1 mil in a quarter. Just for the sake of calculation, if they continue make same amount for the remaining quarter they only gonna only make 3 mil per year. At this price PE ratio is more than 50. Before covid they make less than 1 mil per year and they are heading to that direction. Medtecs is the worst among ppe counters
They should offer $200k to buy off Aspen Glove
Aspen may consider
By the time the factory is ok
Demand drops
Aspen may consider
By the time the factory is ok
Demand drops
jackjack ( Date: 22-Nov-2021 20:17) Posted:
|
I see it kinda dumb, after gloves supply have been increasing and gone oversupply, now they only want tap in. After so many years still a silly management
ttbanthony ( Date: 22-Nov-2021 20:11) Posted:
|
Will we see 20cts tomorrow?
jackjack ( Date: 22-Nov-2021 20:10) Posted:
|
They are investing in glove meaning glove demand still very strong
So, sell medtec and buy glove stock
So, sell medtec and buy glove stock
Q3 profit less than 1Mil. What did i said? Second half performance going to be worse. Where is that Akasa now?? Ohh ya he says he not going to post anymore. After being hired by Yang Yang come promote to trick people buy, now faster hide himself before all the truth being told
With all the talking and long term nonsense you guys have been talking, see whether you still can still trust these promoter and this company management or not =)
With all the talking and long term nonsense you guys have been talking, see whether you still can still trust these promoter and this company management or not =)
Announcement on Selected Financial Information for the Nine Months Ended 30 September 2021 and FY2021 Outlook The Board of Directors (the " Board" ) of Medtecs International Corporation Limited (the " Company" and together with its subsidiaries, the " Group" ) wishes to update shareholders regarding selected financial results of the Group for the nine months ended 30 September 2021 (&ldquo 9M 2021&rdquo ).
Demand for the Group&rsquo s personal protective equipment (" PPE" ) has lowered compared to previous quarters due to completion of stock-piling exercises by our existing customers in 2020, the subsequent inventory adjustment attributable to certain customers, and the stabilisation of the supply and prices of the PPE market globally. Profitability also declined substantially due to lower revenues, a shift in the Group&rsquo s revenue stream to lower-margined OEM items, and higher selling and distribution costs. Based on the preliminary assessment of the latest unaudited consolidated management accounts, as set out in the following table, in 9M 2021, the Group&rsquo s total revenues decreased to US$115.36 million, with after-tax net profit decreasing by 77% to US$19.26 million, compared to the same period last year. 
The Group has prioritised investment in building its &ldquo Medtecs&rdquo and &ldquo CoverU&rdquo brands and in advertising and distribution of its products as we aim to increase Business to Consumer (B2C) sales through major chain stores, pharmacies and supermarkets.
In addition, the Group makes full use of e-commerce platforms such as Amazon, Alibaba, Shopee and Medtecs Express through its business model of &ldquo Source and Sell Globally&rdquo to further promote growth in its retail business. The Group remains active in securing stock-piling government contracts and has several ongoing stock-piling projects for PPEs and military uniforms in the Philippines.
As part of its growth strategy, the Group intends to set up a glove manufacturing facility in Cambodia to expand its production capacity and product offering with a view to ultimately building a resilient global PPE supply chain. Please refer to the Company&rsquo s SGXNET announcement dated 22 November 2021 for further information.
We are also exploring the possibility of foraying into the renewable energy market to develop another growth driver and will provide further details to shareholders if and when these materialise. Barring unforeseen circumstances, the Company expects to remain profitable for the fourth quarter of the financial year ending 31 December 2021 (" FY2021" ) and for FY2021 as a whole however, we expect our sales and profitability for the second half of FY2021 to be lower than that of the first half of FY2021. This announcement is based on a preliminary assessment of the latest unaudited consolidated 2 management accounts of the Group and is not based on any financial figures or information which have been audited or reviewed by the Group' s auditors. Accordingly, shareholders are cautioned not to place undue reliance on forward-looking statements within this announcement, which are based on the current view of management regarding future events. The Company will provide further details of the Group&rsquo s performance as and when appropriate (including providing relevant business updates between the announcements of its financial results). Submitted by Mr Clement Yang, Executive Chairman, on 22 November 2021 to the SGX-ST
 
Demand for the Group&rsquo s personal protective equipment (" PPE" ) has lowered compared to previous quarters due to completion of stock-piling exercises by our existing customers in 2020, the subsequent inventory adjustment attributable to certain customers, and the stabilisation of the supply and prices of the PPE market globally. Profitability also declined substantially due to lower revenues, a shift in the Group&rsquo s revenue stream to lower-margined OEM items, and higher selling and distribution costs. Based on the preliminary assessment of the latest unaudited consolidated management accounts, as set out in the following table, in 9M 2021, the Group&rsquo s total revenues decreased to US$115.36 million, with after-tax net profit decreasing by 77% to US$19.26 million, compared to the same period last year. 
The Group has prioritised investment in building its &ldquo Medtecs&rdquo and &ldquo CoverU&rdquo brands and in advertising and distribution of its products as we aim to increase Business to Consumer (B2C) sales through major chain stores, pharmacies and supermarkets.
In addition, the Group makes full use of e-commerce platforms such as Amazon, Alibaba, Shopee and Medtecs Express through its business model of &ldquo Source and Sell Globally&rdquo to further promote growth in its retail business. The Group remains active in securing stock-piling government contracts and has several ongoing stock-piling projects for PPEs and military uniforms in the Philippines.
As part of its growth strategy, the Group intends to set up a glove manufacturing facility in Cambodia to expand its production capacity and product offering with a view to ultimately building a resilient global PPE supply chain. Please refer to the Company&rsquo s SGXNET announcement dated 22 November 2021 for further information.
We are also exploring the possibility of foraying into the renewable energy market to develop another growth driver and will provide further details to shareholders if and when these materialise. Barring unforeseen circumstances, the Company expects to remain profitable for the fourth quarter of the financial year ending 31 December 2021 (" FY2021" ) and for FY2021 as a whole however, we expect our sales and profitability for the second half of FY2021 to be lower than that of the first half of FY2021. This announcement is based on a preliminary assessment of the latest unaudited consolidated 2 management accounts of the Group and is not based on any financial figures or information which have been audited or reviewed by the Group' s auditors. Accordingly, shareholders are cautioned not to place undue reliance on forward-looking statements within this announcement, which are based on the current view of management regarding future events. The Company will provide further details of the Group&rsquo s performance as and when appropriate (including providing relevant business updates between the announcements of its financial results). Submitted by Mr Clement Yang, Executive Chairman, on 22 November 2021 to the SGX-ST
 
Announcement on Selected Financial Information for the Nine Months Ended 30 September
2021 and FY2021 Outlook..
https://links.sgx.com/1.0.0/corporate-announcements/MA7XC2AYOI9HCLSW/691741_Medtecs%20-%20Voluntary%20Business%20Updates%20and%209M2021%20Financial%20Information_Final_22%20Nov%202021%20v2.pdf
seems very close to breaking new low again
keep it up medtecs
keep it up medtecs
A week has passed with the rising cases news.... what other kinds of news/catalyst to spur the BBs/investors interest?
JessTrang ( Date: 14-Nov-2021 00:09) Posted:
|
Medtecs is attending a trade fair&ndash MEDICA 2021 at Germany, Messe Dü sseldorf from the 15th  to 18th Nov. What a coincidence that the cases is very high there. Hope Medtecs can get some contracts there.
What u and LT posted are correct. Theoretically.
Practically, it' s JJ who is right practically all the time as the price sort of follow what he says since many months ago when it was probably > $1. Just opinion.
Got to respect him, though don quite like what he predicts. But whatodo. Waiting for him to change the tune lah.
Practically, it' s JJ who is right practically all the time as the price sort of follow what he says since many months ago when it was probably > $1. Just opinion.
Got to respect him, though don quite like what he predicts. But whatodo. Waiting for him to change the tune lah.

MTHIT5 ( Date: 19-Nov-2021 13:29) Posted:
|
If you follow the thread you will know i have said before, if that someone want to trash talk, then trash talk is what you get. Time to time come here trash talk for entertainment. Who knows now company themselves come out tell everyone what i have been saying. Straight away shoot down all these clowns' claims. Haiyaaa spoil the fun
tritonyeah6666 ( Date: 19-Nov-2021 11:14) Posted:
|
Profitable and undervalued, and owner share is less than 20%? Where are the corporate vultures to target takeover? Or friendly corporate investors? Maybe 3M will come along to invest ...US stocks are so rich now. This guy is ripe for corporate actions
MTHIT5 ( Date: 19-Nov-2021 13:29) Posted:
|
Agreeable. that is why I brought some few days ago. They have cash S$61m, at this low proce, they should buy back 10%x550m=55mx0.31c=17m. If the price keep going lower, they should delist the company & list elsewhere like Taiwan (valuation is better).
They are changing the CFO and I think we will see change in the company, like share buyback or delist or relist etc. Delist may be an option now as it cost only 93m (550m shares- TaiwanTDR shares -boss share 10%=300m shares estimated). They have cash 61m, add this year profit S$40m (estimated). That is more than enough to delist.(no need loan). DYODD.
They are changing the CFO and I think we will see change in the company, like share buyback or delist or relist etc. Delist may be an option now as it cost only 93m (550m shares- TaiwanTDR shares -boss share 10%=300m shares estimated). They have cash 61m, add this year profit S$40m (estimated). That is more than enough to delist.(no need loan). DYODD.
Longtermer ( Date: 19-Nov-2021 12:35) Posted:
|
Company has cash and receiveables of 150m (from H1 report) and still making profits going fwd.
The NAV is 255m or about 46c..
SGX trading at 31c and mkt cap of 170m (close to the cash and the cash to be received of 150m).
Current price is 15c below net asset value per share..
TDR hovering around 130 or 63.5c.
The Taiwanese investors are more savy and consistent imo.
Dyodd, think through and then invest or trade wisely.
 
Likely Priced in already
Stocky901 ( Date: 19-Nov-2021 12:08) Posted:
|
It seems the profit guidance has not much impacts to the price. Hmmm 🤔 🤔